{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe&page=5",
    "query": {
      "intervention": "Syringe",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 1364,
    "total_pages": 137,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T16:37:48.369Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03187080",
      "title": "Enhanced Recovery Strategies in Elective Breast Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain, Acute",
        "Nausea",
        "Vomiting, Postoperative",
        "Opioid Use",
        "Satisfaction"
      ],
      "interventions": [
        {
          "name": "Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline",
          "type": "PROCEDURE"
        },
        {
          "name": "Enhanced recovery after breast surgery (ERABS) strategies",
          "type": "OTHER"
        },
        {
          "name": "Sham paravertebral block using saline",
          "type": "PROCEDURE"
        },
        {
          "name": "Paravertebral block using local anesthetic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 113,
      "start_date": "2017-10-19",
      "completion_date": "2021-06-15",
      "has_results": true,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03187080"
    },
    {
      "nct_id": "NCT02678988",
      "title": "A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "AI-1000 G2",
          "type": "DEVICE"
        },
        {
          "name": "PFS-NSD",
          "type": "DEVICE"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 189,
      "start_date": "2016-02",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 3,
      "location_summary": "Lenexa, Kansas • Marlton, New Jersey • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02678988"
    },
    {
      "nct_id": "NCT05162027",
      "title": "Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Temporomandibular Disorders"
      ],
      "interventions": [
        {
          "name": "Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 5,
      "start_date": "2022-05-26",
      "completion_date": "2023-01-03",
      "has_results": true,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05162027"
    },
    {
      "nct_id": "NCT00066066",
      "title": "Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Periodontitis",
        "Periodontal Diseases"
      ],
      "interventions": [
        {
          "name": "Scaling and root planing",
          "type": "PROCEDURE"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin",
          "type": "DRUG"
        },
        {
          "name": "Doxycycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "The Forsyth Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2003-07",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2013-04-22",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066066"
    },
    {
      "nct_id": "NCT04072822",
      "title": "Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcoholic Hepatitis"
      ],
      "interventions": [
        {
          "name": "Anakinra and Zinc",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2020-07-10",
      "completion_date": "2022-08-12",
      "has_results": true,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04072822"
    },
    {
      "nct_id": "NCT00911170",
      "title": "PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer",
        "Colon Cancer",
        "Colorectal Cancer",
        "Fever",
        "Locally Advanced",
        "Metastatic Colorectal Cancer",
        "Neutropenia",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 847,
      "start_date": "2009-11-03",
      "completion_date": "2015-01-02",
      "has_results": true,
      "last_update_posted_date": "2017-12-29",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 72,
      "location_summary": "Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00911170"
    },
    {
      "nct_id": "NCT03682770",
      "title": "Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching dupilumab",
          "type": "DRUG"
        },
        {
          "name": "AR101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 148,
      "start_date": "2018-10-03",
      "completion_date": "2021-07-23",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682770"
    },
    {
      "nct_id": "NCT01833754",
      "title": "Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Romosozumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-04-22",
      "completion_date": "2014-02-19",
      "has_results": true,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 5,
      "location_summary": "Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Orangeburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01833754"
    },
    {
      "nct_id": "NCT04701983",
      "title": "Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Itepekimab SAR440340",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 1127,
      "start_date": "2020-12-16",
      "completion_date": "2025-08-27",
      "has_results": true,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 75,
      "location_summary": "Birmingham, Alabama • Jasper, Alabama • Chandler, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04701983"
    },
    {
      "nct_id": "NCT00825786",
      "title": "Ultrasound Guided Supraclavicular Nerve Block",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Local Anesthetic"
      ],
      "interventions": [
        {
          "name": "Ropivacaine",
          "type": "DRUG"
        },
        {
          "name": "Mepivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 103,
      "start_date": "2008-09",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-10-29T16:37:48.369Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00825786"
    }
  ]
}